ACADIA Pharmaceuticals Inc.

DB:DR6 Stock Report

Market Cap: €2.7b

ACADIA Pharmaceuticals Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Catherine Owen Adams

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure1.3yrs
Board average tenure9yrs

Recent management updates

Recent updates

CEO

Catherine Owen Adams (54 yo)

less than a year

Tenure

Ms. Catherine E. Owen Adams is CEO & Director of ACADIA Pharmaceuticals Inc. from September 23, 2024. Ms. Owen Adams served as Director of OptiNose US, Inc. since July 2020 until September 24, 2024. She se...

Leadership Team

NamePositionTenureCompensationOwnership
Mark Schneyer
Executive VP & CFO3.3yrsUS$2.59m0.032%
€ 875.1k
Stephen Davis
Consultantless than a yearUS$7.59m0.11%
€ 3.1m
Brendan Teehan
Non-Executive Employeeless than a yearUS$2.62m0.037%
€ 1.0m
Catherine Owen Adams
CEO & Directorless than a yearno datano data
James Kihara
VP, Chief Accounting Officer & Corporate Controller4.3yrsno data0.012%
€ 326.2k
Elizabeth Thompson
Executive VP and Head of Research & Developmentless than a yearno datano data
Benir Ruano
Senior Vice President of Technical Development2.1yrsno datano data
Albert Kildani
Senior Vice President of Investor Relations & Corporate Communications1.3yrsno datano data
Jennifer Rhodes
Executive VPless than a yearno datano data
Rob Ackles
Senior VP & Chief People Officer2.9yrsno datano data
Bob Mischler
Senior Vice President of New Product Planning & Strategyno datano datano data
Ponni Subbiah
SVP, Global Head of Medical Affairs & Chief Medical Officer5.1yrsno datano data

1.3yrs

Average Tenure

54yo

Average Age

Experienced Management: DR6's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Catherine Owen Adams
CEO & Directorless than a yearno datano data
Laura Brege
Independent Director16.6yrsUS$392.75k0.012%
€ 330.9k
Julian Baker
Independent Director9yrsUS$377.75k0.062%
€ 1.7m
Paul Anderson
Member of the Scientific and Clinical Advisory Boardno datano datano data
Edmund Harrigan
Independent Director9.1yrsUS$387.75k0.015%
€ 421.3k
Daniel Soland
Independent Director9.8yrsUS$387.75k0.021%
€ 569.1k
Arvid Carlsson
Member of the Scientific and Clinical Advisory Boardno datano datano data
Carol Tamminga
Member of the Scientific and Clinical Advisory Boardno datano datano data
Herbert Meltzer
Member of the Scientific and Clinical Advisory Boardno datano datano data
James Daly
Independent Director8.9yrsUS$387.75k0.015%
€ 404.9k
Stephen Biggar
Independent Chairman of the Board11.9yrsUS$432.75k0.062%
€ 1.7m
Elizabeth Garofalo
Independent Director4.3yrsUS$377.75k0.014%
€ 369.7k

9.0yrs

Average Tenure

66yo

Average Age

Experienced Board: DR6's board of directors are considered experienced (9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 04:12
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ACADIA Pharmaceuticals Inc. is covered by 37 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert LeBoyerAegis Capital Corporation
Joel BeattyBaird
Ishan MajumdarBaptista Research